Literature DB >> 20508947

Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior.

Xin-Yuan Lu1, Tao Xi, Wan-Yee Lau, Hui Dong, Zhi-Hong Xian, Hua Yu, Zhen Zhu, Feng Shen, Meng-Chao Wu, Wen-Ming Cong.   

Abstract

PURPOSE: Increasing evidence has suggested that tumor size is one of the independent prognostic factors of patients with hepatocellular carcinoma (HCC). However, the criteria used to determine when HCC should be classified as small remain controversial. Our objective was to evaluate the relationship between the size of HCC and its clinicopathological features.
METHODS: A retrospective study on 618 patients who underwent partial hepatectomy for solitary HCC was performed. These patients were divided into Groups 1-5 according to the tumor diameter: ≤ 1, 1.1-2, 2.1-3, 3.1-5 and >5 cm, respectively. The clinicopathological variables of the patients in each group were compared statistically.
RESULTS: Except for the microHCC (≤ 1 cm) which differed significantly from the other four groups in the clinicopathological variables, almost no differences existed among HCC ranging from 1 to 3 cm, or HCCs > 3 cm. If ≤ 3 cm was used as the cut-off point for small HCC (SHCC), and >3 cm for large HCC (LHCC), significant differences (P < 0.05-0.01) were observed between SHCC and LHCC in: histological grades I-II (48.0 vs. 19.4 %), capsular invasion (15.4 vs. 36.3%), tumor thrombi (6.9 vs. 23.5%), satellite nodules (12.3 vs. 35.5%), noninvasive growth patterns (69.6 vs. 25.4%), the overall survival (OS, 119.6 ± 34.7 vs. 68.5 ± 6.6 months), and the recurrence-free survival (RFS, 67.0 ± 16.7 vs. 29.5 ± 3.2 months). Multivariate Cox regression analyses show that tumor size >3 cm was one of the independent prognostic factors for both OS and RFS.
CONCLUSIONS: The 3 cm cutoff seems to best determine the biological behavior and clinical prognosis of patients undergoing partial hepatectomy for early stage HCC. Overall, HCC smaller than 3 cm in diameter was closely related with a better prognosis which reflected the relatively benign pathobiological features at an early developmental stage. As HCC > 3 cm exhibited a tendency towards more aggressive behavior, we suggest that HCC ≤ 3 cm in diameter should be used as a critical size of SHCC at which curative treatment achieves better long-term survivals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508947     DOI: 10.1007/s00432-010-0909-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma.

Authors:  Toyoki Moribe; Norio Iizuka; Toshiaki Miura; Naoki Kimura; Shigeru Tamatsukuri; Hideo Ishitsuka; Yoshihiko Hamamoto; Kazuhiko Sakamoto; Takao Tamesa; Masaaki Oka
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

3.  Clinicopathological studies of minute hepatocellular carcinoma. Analysis of 20 cases, including 4 with hepatic resection.

Authors:  K Okuda; T Nakashima; H Obata; Y Kubo
Journal:  Gastroenterology       Date:  1977-07       Impact factor: 22.682

4.  A histopathologic study of early hepatocellular carcinoma.

Authors:  Y Kondo; Y Niwa; B Akikusa; H Takazawa; A Okabayashi
Journal:  Cancer       Date:  1983-08-15       Impact factor: 6.860

5.  Surgery of small hepatocellular carcinoma. Analysis of 144 cases.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; Z C Ma; R Yang; J Z Lu; Z Y Lin; B H Yang
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 7.  Atypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity.

Authors:  Masatoshi Kudo
Journal:  Intervirology       Date:  2004       Impact factor: 1.763

Review 8.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

10.  Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score.

Authors:  Hobyung Chung; Masatoshi Kudo; Shunsuke Takahashi; Satoru Hagiwara; Yasuhiro Sakaguchi; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toyokazu Fukunaga; Takashi Matsunaga
Journal:  J Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 4.029

View more
  28 in total

1.  Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes.

Authors:  Yun Xu; Qiang Shen; Pei Liu; Zhongqi Xu; Panpan Wu; Zhenghua Lu; Yi Chen; Bin Huang; Guojun Qian
Journal:  Eur Radiol       Date:  2017-02-10       Impact factor: 5.315

2.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

3.  Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma.

Authors:  Long-Hai Feng; Hui Dong; Wan-Yee Lau; Hua Yu; Yu-Yao Zhu; Yun Zhao; Yu-Xi Lin; Jia Chen; Meng-Chao Wu; Wen-Ming Cong
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-14       Impact factor: 4.553

4.  Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients following hepatic resection.

Authors:  Chih-Jan Ko; Su-Yu Chien; Chen-Te Chou; Li-Sheng Chen; Mei-Ling Chen; Yao-Li Chen
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

5.  Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Sevil Uygun Ilikhan; Muammer Bilici; Hatice Sahin; Ayşe Semra Demir Akca; Murat Can; Ibrahim Ilker Oz; Berrak Guven; M Cagatay Buyukuysal; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 6.  Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging.

Authors:  Jens Ricke; Max Seidensticker; Konrad Mohnike
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

7.  The Predictors of Microscopic Vessel Invasion Differ Between Primary Hepatocellular Carcinoma and Hepatocellular Carcinoma with a Treatment History.

Authors:  Yukiyasu Okamura; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Takeshi Aramaki; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

8.  Small hepatocellular carcinoma: current and future approaches.

Authors:  Wen-Ming Cong; Meng-Chao Wu
Journal:  Hepatol Int       Date:  2013-08-06       Impact factor: 6.047

9.  Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.

Authors:  Chang Liu; Guang-Qin Xiao; Lu-Nan Yan; Bo Li; Li Jiang; Tian-Fu Wen; Wen-Tao Wang; Ming-Qing Xu; Jia-Yin Yang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

10.  MELD score and AST-to-platelet ratio index (APRI) predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study.

Authors:  Joy Sarkar; Thomas DeLeon; Linda L Wong
Journal:  Hepatoma Res       Date:  2017-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.